Phase 2b trial in 4,936 Gambian children aged 6-18 months: the oral ETEC vaccine ETVAX did not meet its primary endpoint, efficacy 26.6% (95% CI -58.3 to 66.0) against moderate-to-severe ETEC diarrhoea vs placebo. Serious adverse events were 1.0% vs 1.3%.
RCTn = 4,936
Hossain et al. Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial